Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sexual selection and ecological-demographical context drive the evolution of same-sex sexual behaviour.

Scientific reports·2026

Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026

Same author

Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence flow cytometry.

Clinical chemistry and laboratory medicine·2026

Same author

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Therapeutic advances in neurological disorders·2026

Same author

Effect of Adhesive Type and Surface Preparation on the Debonding Behavior of Glass and Carbon Fiber Reinforced Epoxy Adhesive Joints.

Materials (Basel, Switzerland)·2026

Same author

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Mar 17, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Platelet concentrates: Balancing between efficacy and safety?

Miguel Lozano¹, Joan Cid¹

¹University Clinic Hospital, Biomedical Diagnosis Center, IDIBAPS, Department of Hemotherapy and Hemostasis, Barcelona, Spain.

Presse Medicale (Paris, France : 1983)

|August 1, 2016

Summary

Platelet transfusions are vital but carry risks like bacterial contamination. Pathogen inactivation methods eliminate sepsis risk but may affect platelet function, necessitating increased usage.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Published on: January 4, 2019

Related Experiment Videos

Last Updated: Mar 17, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Published on: January 4, 2019

Area of Science:

Hematology
Transfusion Medicine
Infectious Disease Prevention

Background:

Platelet transfusions are essential for treating platelet disorders, with millions administered globally.
Bacterial contamination poses a significant non-immune risk, with current culture methods reducing but not eliminating septic reactions.
Pathogen inactivation (PI) technologies offer a solution to eliminate bacterial sepsis risk in platelet transfusions.

Purpose of the Study:

To evaluate the efficacy and impact of pathogen inactivation (PI) methods in platelet transfusions.
To assess the risk of bacterial contamination in platelet transfusions and the limitations of current detection methods.
To understand the trade-offs between eliminating sepsis risk and potential effects on platelet viability and utilization.

Main Methods:

Review of existing literature on platelet transfusion practices, bacterial contamination, and pathogen inactivation technologies.
Analysis of the effectiveness of bacterial culture methods versus PI methods in preventing septic reactions.
Examination of the in vitro and in vivo effects of PI technologies on platelet parameters, recovery, and survival.

Main Results:

Pathogen inactivation methods have proven effective in inactivating bacteria, with no reported septic reactions linked to PI-treated products.
PI technologies can impact platelet in vitro parameters and reduce in vivo recovery and survival.
Despite potential effects, PI is considered a necessary measure to completely eliminate bacterial sepsis risk.

Conclusions:

Pathogen inactivation is a crucial advancement for ensuring the safety of platelet transfusions by eliminating bacterial sepsis.
While PI technologies may increase platelet utilization due to effects on platelet parameters, this is an acceptable cost for enhanced patient safety.
Further research may be needed to optimize PI methods to minimize effects on platelet viability while maintaining efficacy.